April 21st, 2021

HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout

Read More »
March 31st, 2021

Molecular Genetics and Metabolism Publishes Primary Pharmacology Data Supporting HemoShear’s HST5040 as a Potential Treatment for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

Read More »
February 22nd, 2021

BioCentury: $40M series A sets up HemoShear to complete evolution from service play to clinical-stage biotech 

Read More »
February 10th, 2021

HemoShear Therapeutics Raises $40 Million in Series A Financing to Advance Rare Disease Portfolio

Read More »
January 28th, 2021

HemoShear announces appointment of Vice Presidents

Read More »
December 16th, 2020

HemoShear Therapeutics’ HST5040 Receives U.S. Orphan Drug Designations for Treatment of Methylmalonic Acidemia and Propionic Acidemia

Read More »
December 10th, 2020

HemoShear Therapeutics Identifies Novel Drug Target to Treat NASH in Drug Discovery Partnership with Takeda

Read More »
November 30th, 2020

Shear Insights: HemoShear Therapeutics to Present at Piper Sandler Annual Healthcare Conference

Read More »
November 12th, 2020

Shear Insights: HemoShear Therapeutics Launches Pilot Study to Evaluate Neuropsychological Assessments for MMA and PA

Read More »
October 21st, 2020

HemoShear Therapeutics Enters into Rare Liver Disease Research Collaboration with Takeda

Read More »
September 29th, 2020

Shear Insights: Mavis Waller Appointed to Vice President, Clinical Operations as HemoShear Readies for Clinical Trials

Read More »
August 25th, 2020

HemoShear Therapeutics featured as NIH Small Business Innovation Research Grant Success Story

Read more at SBIR/STTR
View More +


HemoShear Therapeutics, Inc.
501 Locust Avenue
Suite 301
Charlottesville, Virginia 22902